June 29, 2020 10:53 AM EDT

EMA removes negative note on label of PTC's Duchenne drug; GSK, Akebia win Japan OK for oral anemia drugs

John Carroll

Editor & Founder

Amber Tong

→ PTC Therapeutics $PTCT won conditional approval to market ataluren for Duchenne MD in Europe way back in 2014 — despite the fact that all the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA removes negative note on label of PTC's Duchenne drug; GSK, Akebia win Japan OK for oral anemia drugs

John Carroll

Editor & Founder

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

EMA re­moves neg­a­tive note on la­bel of PTC's Duchenne drug; GSK, Ake­bia win Japan OK for oral ane­mia drugs

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

EMA removes negative note on label of PTC's Duchenne drug; GSK, Akebia win Japan OK for oral anemia drugs